Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 18/20 | 0.62 |
| ▸ | EGFR | P00533 | 16/20 | 0.62 |
| ▸ | ERBB4 | Q15303 | 9/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | RGS12 | O14924 | 1/20 | 0.62 |
| ▸ | GMNN | O75496 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | RAF1 | P04049 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.62 |
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | APEX1 | P27695 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6891343 | 0.83 | ERBB2 (0.62) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6773200 | 0.82 | ERBB2 (0.69) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6891340 | 0.81 | ERBB2 (0.62) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL6883721 | 0.81 | ERBB2 (0.76) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL8365630 | 0.80 | ERBB2 (0.73) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL2248227 | 0.80 | ERBB2 (0.60) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL2249076 | 0.80 | ERBB2 (0.67) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL3323462 | 0.80 | ERBB2 (0.74) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL31061501 | 0.79 | ERBB2 (0.76) | ERBB2EGFRERBB4MEN1RGS12 | |
| SCHEMBL8561085 | 0.79 | ERBB2 (0.76) | ERBB2EGFRERBB4MEN1RGS12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6828320-B2 | Enzyme inhibitors; anticancer agents | SMITHKLINE BEECHAM CORPORATION | 2004-12-07 | — | — | US | disclosed |
| US-20020147214-A1 | Heterocyclic compounds | NOVARTIS AG (CH) | 2002-10-10 | — | — | US | disclosed |
| US-6391874-B1 | ANTICARCINOGENIC AGENTS; SKIN DISORDERS | SMITHKLINE BEECHAM CORPORATION | 2002-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147214-A1 | Heterocyclic compounds | BRAF, ABL1, CSK | ERBB2 35/4885EGFR 354/4885ERBB4 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.